-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, a research article was published in Arthritis & Rheumatology, an authoritative journal in the field of rheumatology and immunology .
immunity
The researchers conducted a two-year double-blind, randomized, controlled trial on 104 erosive gout participants who received oral uric acid-lowering therapy (ULT) and serum uric acid ≥ 0.
guide
The researchers used a standardized protocol (using the maximum approved doses of allopurinol, probenecid, febuxostat, and benzbromarone) to titrate oral ULT to a uric acid reduction target
Although compared with the standard target group, the serum uric acid of the intensive target group was significantly lower (P=0.
Quality of Life
It can be seen that compared with the target of serum uric acid lower than 0.
Compared with the target of serum uric acid lower than 0.
Original source:
Nicola Dalbeth,et al.
Intensive serum urate lowering with oral urate- lowering therapy for erosive gout: A randomized double-blind controlled trial
in this message
